We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Plans Alzheimer’s BLA Filing Later This Year Following Aducanumab’s Model
Eli Lilly Plans Alzheimer’s BLA Filing Later This Year Following Aducanumab’s Model
Eli Lilly plans to pursue accelerated approval of its Alzheimer’s treatment donanemab, using the same fast-track pathway Biogen used for its controversial Alzheimer’s drug Aduhelm.